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ANCA = antineutrophil cytoplasmic antibody; SAcP = staphylococcal acid phosphatase; SAg = superantigen; SpA = staphylococcal protein A;
TCR Vβ = T-cell receptor V-beta chains; TSST = toxic-shock-syndrome-toxin; WG = Wegener’s granulomatosis.
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Introduction
Wegener’s granulomatosis (WG) is a form of systemic vas-
culitis that predominantly affects small- and medium-sized
blood vessels. Frequently commencing with general, aspe-
cific symptoms, the disease is frequently hallmarked by the
presence of autoantibodies (antineutrophil cytoplasmic anti-
bodies [ANCA]) [1,2] directed predominantly against the
myeloid enzyme proteinase 3 (in 80% of WG patients) and,
in a minority of cases, against myeloperoxidase [3,4]. Mani-
festations of granulomatous inflammation in the upper and
lower airways, vasculitis and necrotizing glomerulonephritis
characterize the classical clinical picture of WG [5].
In WG, respiratory tract infections frequently precede or
accompany initial symptoms [6,7]. Moreover, treatment of
WG limited to the airways with the antibiotic co-trimoxa-
zole often leads to achievement of stable remission [8]
and prophylactic treatment with this drug reduced the inci-
dence of disease relapses [9]. Although the beneficial
effect of co-trimoxazole may also be explained by its
immunosuppressive effect [10] and although a bacterial
agent was originally not pinpointed [9,11], these findings
were taken as indications that bacterial infections may be
essentially implicated in the pathogenesis of WG. In
search of a specific pathogenic bacterial agent we have
shown that chronic nasal carriage of Staphylococcus
aureus is approximately three times higher in WG patients
than in healthy individuals [11], which may, at least in part,
be due to hospitalization and/or immunosuppressive treat-
ment. In contrast to healthy individuals who are frequently
exposed to S. aureus (e.g. hospital personnel), but for
whom carriage of this bacterium remains inconsequential,
in WG patients S. aureus constitutes a risk factor for
disease exacerbation [11]. This may possibly be due to a
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Abstract
Wegener’s granulomatosis (WG) is a form of systemic vasculitis. It is characterized by granulomatous
inflammation in the upper and lower airways, vasculitis and necrotizing glomerulonephritis, and is
strongly associated with antineutrophil cytoplasmic antibodies against proteinase 3. Since the etiology
of the disease is not clear, treatment, consisting of corticosteroids and immunosuppressives, is
nonspecific and associated with severe side effects. Pinpointing the trigger(s) of the disease would
highly improve treatment. Clinical evidence shows that an infectious agent, the bacterium
Staphylococcus aureus, is a risk factor for disease relapse, suggesting its involvement in the
pathogenesis of WG. Here we review both clinical and experimental data that either indicate or
support a role for S. aureus in WG.
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dysregulated immune system and frequent nasal lesions
present in these patients. Thus, these data ask for explo-
ration of the potential mechanisms mediating staphylococ-
cal pathogenicity. Recently obtained data supporting
various pathogenic mechanisms related to S. aureus will
be reviewed below.
Staphylococcal superantigens and WG
In vitro and in animal models S. aureus acts as a potent
immunostimulator, effecting polyclonal proliferation of T-
and B cells, secretion of immunoglobulins, and cytokine
production. The main influence of S. aureus on immuno-
competent cells is exerted by its exotoxins. Three classes
of staphylococcal exotoxins have been described so far:
the staphylococcal enterotoxins, exfoliative toxins, and the
toxic-shock-syndrome-toxin-1 (TSST-1) [12]. Based on
their exceptionally strong capacity to stimulate T cells in a
nonantigen specific way, exotoxins were termed ‘super-
antigens’ (SAg) [13]. Moreover, staphylococcal protein A
(SpA), a common component of the staphylococcal cell
wall, has been recognized as a B-cell SAg [14].
T-cell SAg
T-cell SAg can simultaneously bind to MHC class II mole-
cules outside the peptide-binding groove and to conserved
regions of specific families of T-cell receptor V-beta chains
(TCR Vβ) [13], independently of ligand specificity of T
cells. As a consequence, virtually all T cells expressing a
SAg-reactive TCR Vβ chain are stimulated to proliferate.
In the absence of more formal proof, exaggerated prolifer-
ation of SAg-specific T-cell subsets has been regarded as
an indicator of SAg involvement in disease. Indeed, the
presence of abnormal expansions of Vβ2-expressing T
cells during the active phase of Kawasaki disease (a form
of large- to medium-size vessel vasculitis) together with
the detection of TSST-1-producing S. aureus in this
disease, strongly suggested a causal link between
immune dysbalance, disease activity and SAg [15–18]. In
WG, several groups have reported expansions of various
T-cell subsets but they found no obvious preferential
skewing of any particular Vβ subset [19,20]. Moreover, we
were unable to demonstrate a link between staphylococ-
cal SAg and peripheral blood T-cell expansions in patients
with WG, since expansions of peripheral blood T-cell
subsets were not associated with the simultaneous pres-
ence of SAg-positive S. aureus strains (Popa et al. manu-
script in preparation).
These findings, however, do not exclude a pathophysio-
logic role for staphylococcal SAg in WG. In a study
including 709 S. aureus strains (isolated from nasal cul-
tures from 63 WG patients followed over a time period of
6 years) we screened for genes encoding the staphylo-
coccal enterotoxin SAg SEA-E, exfoliative toxin A and
TSST-1. We assessed the risk for development of a
disease relapse within three months from the appearance
of one of these SAgs. We again confirmed the association
of the presence of S. aureus with a risk for relapse of WG.
In addition, we found that the risk for relapse was modu-
lated according to the presence and type of SAg, with
tsst-1 being associated with a higher risk for relapse (rela-
tive risk 14.5, 95% confidence interval 2.4–85.4). In WG,
a pathogenic role for S. aureus in general, and the SAg
TSST-1 in particular, thus cannot be excluded and the
mechanisms of pathogenicity should be investigated
further. An important goal for investigation will be the
demonstration of SAg in the blood stream and lymphoid
organs of WG patients.
B-cell SAg
The B-cell SAg, SpA, is a component of most clinical strains
of S. aureus. The superantigenic activity of SpA is induced
after binding to membrane immunoglobulin heavy chains
encoded by VH3 family genes [14], which constitute
15–50% of total human IgM, IgG and IgA, and effects mito-
genicity and induction of polyclonal antibody responses.
In WG, the possible implication of SpA can be conjec-
tured from the amino acid sequence of WG-associated
ANCA. Thus, the presence of ANCA with a VH3-encoded
heavy chain would indicate potential binding capacity of
SpA. Based on an anecdotic report of VH3-encoded
ANCA [21] it is conceivable that, in the presence of SpA,
ANCA-producing B cells could be induced to proliferate,
resulting in an amplification of the pool of autoantibodies.
The fact that carriage of S. aureus in patients with WG
was associated with increased ANCA positivity during
follow-up [11] supports this potential mechanism.
Staphylococcal acid phosphatase
In patients with S. aureus-associated glomerulonephritis,
high levels of circulating immune complexes are present
which decrease during antibiotic treatment [22,23]. These
findings raise the possibility that specific staphylococcal
molecules may be nephritogenic. One of these molecules
is the cationic acid phosphatase, SAcP [24], which has a
high affinity for the glomerular basement membrane and
can induce glomerulonephritis when perfused in the
kidney of naïve rats [25] or rats immunized with SAcP
[26]. Based on these data, we hypothesized that, in WG,
SAcP may act as a planted antigen by binding to glomeru-
lar basement membrane and vascular endothelium, thus
initiating glomerulonephritis and vasculitis. We found that
SAcP can bind to human umbilical vein endothelial cells
and glomerular endothelial cells in vitro [27] in a charge-
dependent manner, since binding can be blocked by the
negatively charged heparin. Moreover, sera of WG
patients were able to bind SAcP bound to endothelial
cells in vitro [27]. Together with our finding that antibodies
to SAcP are present in WG patients who are S. aureus
carriers, these data suggest that, in vivo, the presence ofSAcP in conjunction with anti-SAcP antibodies may be
nephritogenic and vasculitogenic in WG patients. More-
over, in the presence of SAcP–anti-SAcP immune com-
plexes in the kidney, ANCA may be able to aggravate
glomerulonephritis, as suggested by our studies on the
effect of myeloperoxidase-specific autoantibodies on anti-
glomerular-basement-membrane-mediated glomerular injury
in the rat [28].
Conclusion
To date, despite clinical evidence suggesting that
S. aureus may be implicated in the pathophysiology of
WG, laboratory investigation of the possible mechanisms
by which S. aureus is involved in WG is still scarce.
Besides staphylococcal SAg and SAcP, which have
received some attention, other staphylococcal molecules,
such as hemolysins, teichoic acid, proteoglycans and
DNA-containing CpG motifs, to name only a few, are cur-
rently known as immunomodulators and certainly deserve
further investigation in the context of vasculitis. Moreover,
there are ample in vitro and in vivo data available on the
effect of S. aureus on immunocompetent cells, such as B
and T cells, monocytes and neutrophillic granulocytes, but
also on other cell types, such as endothelial and epithelial
cells. Keeping in mind that in WG, immune dysbalance
can eventually lead to vascular damage, S. aureus as a
trigger and mediator of various pathophysiologic mecha-
nisms is a very attractive target for investigation.
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